Á¦2ȸ AACR-KCA Joint Workshop on Precision Medicine in Cancer ¹× Á¦25Â÷ ´ëÇѾÏÇÐȸ Ãß°è½ÉÆ÷Áö¾ö(2ÀÏÂ÷) : 2022-11-11±³À°ÀÏÀÚ : 2022-11-11
±³À°Àå¼Ò : ¼¿ï·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë ¿Ü 2°³·ë
±³À°ÁÖÁ¦ :
Á¦2ȸ AACR-KCA Joint Workshop on Precision Medicine in Cancer ¹× Á¦25Â÷ ´ëÇѾÏÇÐȸ Ãß°è½ÉÆ÷Áö¾ö(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486
À̸ÞÀÏ :
cancer2@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 11 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 350,000¿ø
ºñ°í 1. »çÀüµî·Ï:1) ȸ¿ø 10¸¸¿ø, 2) ȸ¿ø(¾÷ü), ºñȸ¿ø 15¸¸¿ø, 3) ºñȸ¿ø(¾÷ü) 25¸¸¿ø, 4) Àü°øÀÇ/Çлý 5¸¸¿ø2. ÀϹݵî·Ï:1) ȸ¿ø 20¸¸¿ø, 2) ȸ¿ø(¾÷ü), ºñȸ¿ø 25¸¸¿ø, 3) ºñȸ¿ø(¾÷ü) 35¸¸¿ø, 4) Àü°øÀÇ/Çлý 10¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-11 Crystal 08:30~08:55 Updated results of a phase I trial of PSMA-targeting TGF¥â-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer Naomi B. Hass(University of Pennsylvania Health System, USA)
±³À°½Ã°£ 11-11 Crystal 08:55~09:20 A novel mechanism of targeting both LAG-3 and PD-L1 with a bispecific antibody ¹ÚÀ±(KIST)
±³À°½Ã°£ 11-11 Crystal 09:20~09:45 CAR T-cell based combination immunotherapy for solid tumors Prasad S Adusumilli(Memorial Sloan Kettering Cancer Center, USA)
±³À°½Ã°£ 11-11 Crystal 09:45~10:10 Regulation of T cell immunity in lymph node and tumor ÇÏ»óÁØ(¿¬¼¼´ë)
ÈÞ½Ä 11-11 10:10~10:30 ÈÞ½Ä ()
±³À°½Ã°£ 11-11 Crystal 10:30~10:55 Vaccines targeting mutant KRAS neoantigens in combination with immune checkpoint blockade Neeha Zaidi(The Johns Hopkins Hospital, USA)
±³À°½Ã°£ 11-11 Crystal 10:55~11:20 Determinants of neoantigen validity in cancer immunotherapy ±è±ÇÀÏ(°æÈñ´ë)
±³À°½Ã°£ 11-11 Crystal 11:20~11:45 Identification and characterization tumor-reactive T cells in malignant tumors through TCR analysis Bo Li(UT Southwestern Medical Center, USA)
±³À°½Ã°£ 11-11 Crystal 11:45~12:10 Characterization of tumor antigen-specific T cells in blood and tumors ½ÅÀÇö(KAIST)
ÈÞ½Ä 11-11 12:10~12:20 ÈÞ½Ä ()
±³À°½Ã°£ 11-11 Crystal 12:20~13:00 Take hope further with abemacicilb for HR+, HER2- Breast Cancer patients ¹Ú°æÈ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-11 Emerald 12:20~13:00 Let 1L Esophageal cancer patients start a Whole New World with Pembrolizumab ±èÀÎÈ£(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 11-11 13:00~13:20 ÈÞ½Ä ()
±³À°½Ã°£ 11-11 Crystal 13:20~13:45 PROTAC drugs in oncology: Concepts and cases ÀÌÈÁø(¾÷Å׶ó)
±³À°½Ã°£ 11-11 Crystal 13:45~14:10 Novel radiopharmaceutical therapy ¿ÀÁÖÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-11 Crystal 14:10~14:35 Cancer nanotheranostics ÀÓÇüÁØ(¼¿ï´ë)
±³À°½Ã°£ 11-11 Crystal 14:35~15:00 New therapeutic approaches for the intractable tumors ÀÌÁ¤¹Î(Çѵ¿´ë)
±³À°½Ã°£ 11-11 Emerald 13:20~13:45 Auto-contouring and online adaptive radiotherapy or AI ±èÁø¼º(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-11 Emerald 13:45~14:10 MRI-guided radiotherapy and adaptation ±èÁØ¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-11 Emerald 14:10~14:35 Genomic biomarker of radiotherapy and response prediction Àå¹ü¼·(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-11 Emerald 14:35~15:00 Response prediction of radiotherapy with radiomics ½ÅÀç½Â(»ï¼º¼¿ïº´¿ø)
ÈÞ½Ä 11-11 15:00~15:20 ÈÞ½Ä ()
±³À°½Ã°£ 11-11 Crystal 15:20~15:45 Minimal residual disease in colorectal cancer ÇѼ¼¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-11 Crystal 15:45~16:10 Spatial transcriptomics based on scRNA-sequencing ±èŹÎ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-11 Crystal 16:10~16:35 The telomere maintenance mechanism spectrum and its dynamics in gliomas ¹Úö±â(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-11 Crystal 16:35~17:00 Precision medicine-based platform trial ¹Ú¿¬Èñ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-11 Emerald 15:20~15:45 Complete cytoreductive surgery for resetting PARPi or PD-1i-resistant recurrent ovarian, fallopian tubal, peritoneal carcinoma ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-11 Emerald 15:45~16:10 Role of intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis ±èÁ¾ÇÑ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-11 Emerald 16:10~16:35 Conversion surgery in unresectable pancreatic cancers ÀåÁø¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-11 Emerald 16:35~17:00 Surgical treatment for retroperitoneal sarcoma À̱³¿ø(¼º±Õ°üÀÇ´ë)